Lexicon Pharmaceuticals, Inc. (LXRX)
USD 0.45
(2.46%)
USD 0.45
(2.46%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 229.42 Million USD | 18.08% |
| 2022 | 194.29 Million USD | 41.92% |
| 2021 | 136.9 Million USD | -32.82% |
| 2020 | 203.78 Million USD | -51.21% |
| 2019 | 417.71 Million USD | 47.01% |
| 2018 | 284.13 Million USD | -34.91% |
| 2017 | 436.53 Million USD | -8.22% |
| 2016 | 475.62 Million USD | -27.37% |
| 2015 | 654.83 Million USD | 38.92% |
| 2014 | 471.37 Million USD | 71.93% |
| 2013 | 274.16 Million USD | -26.26% |
| 2012 | 371.77 Million USD | -13.64% |
| 2011 | 430.51 Million USD | 17.34% |
| 2010 | 366.88 Million USD | 42.33% |
| 2009 | 257.76 Million USD | -1.43% |
| 2008 | 261.5 Million USD | -29.19% |
| 2007 | 369.29 Million USD | 94.09% |
| 2006 | 190.26 Million USD | -13.01% |
| 2005 | 218.71 Million USD | 3.18% |
| 2004 | 211.98 Million USD | -25.41% |
| 2003 | 284.19 Million USD | 40.85% |
| 2002 | 201.77 Million USD | -15.92% |
| 2001 | 239.99 Million USD | 8.74% |
| 2000 | 220.69 Million USD | 889.65% |
| 1999 | 22.3 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 373.35 Million USD | -10.51% |
| 2024 Q1 | 417.21 Million USD | 81.85% |
| 2023 FY | 229.42 Million USD | 18.08% |
| 2023 Q4 | 229.42 Million USD | -17.02% |
| 2023 Q1 | 162.71 Million USD | -16.25% |
| 2023 Q3 | 276.47 Million USD | -12.71% |
| 2023 Q2 | 316.72 Million USD | 94.65% |
| 2022 Q3 | 191.68 Million USD | 70.65% |
| 2022 Q2 | 112.32 Million USD | -17.52% |
| 2022 Q1 | 136.17 Million USD | -0.53% |
| 2022 FY | 194.29 Million USD | 41.92% |
| 2022 Q4 | 194.29 Million USD | 1.36% |
| 2021 FY | 136.9 Million USD | -32.82% |
| 2021 Q3 | 172.33 Million USD | 0.38% |
| 2021 Q4 | 136.9 Million USD | -20.55% |
| 2021 Q1 | 193.26 Million USD | -5.17% |
| 2021 Q2 | 171.67 Million USD | -11.17% |
| 2020 Q3 | 178.92 Million USD | -44.53% |
| 2020 Q2 | 322.54 Million USD | -12.96% |
| 2020 Q1 | 370.56 Million USD | -11.29% |
| 2020 FY | 203.78 Million USD | -51.21% |
| 2020 Q4 | 203.78 Million USD | 13.89% |
| 2019 Q4 | 417.71 Million USD | -6.04% |
| 2019 FY | 417.71 Million USD | 47.01% |
| 2019 Q2 | 233.14 Million USD | -9.81% |
| 2019 Q1 | 258.51 Million USD | -9.02% |
| 2019 Q3 | 444.58 Million USD | 90.69% |
| 2018 Q2 | 332.93 Million USD | -13.93% |
| 2018 FY | 284.13 Million USD | -34.91% |
| 2018 Q4 | 284.13 Million USD | -8.4% |
| 2018 Q1 | 386.81 Million USD | -11.39% |
| 2018 Q3 | 310.19 Million USD | -6.83% |
| 2017 Q2 | 363.51 Million USD | -8.26% |
| 2017 Q4 | 436.53 Million USD | 32.49% |
| 2017 FY | 436.53 Million USD | -8.22% |
| 2017 Q1 | 396.26 Million USD | -16.69% |
| 2017 Q3 | 329.48 Million USD | -9.36% |
| 2016 Q3 | 516.94 Million USD | -7.38% |
| 2016 FY | 475.62 Million USD | -27.37% |
| 2016 Q4 | 475.62 Million USD | -7.99% |
| 2016 Q1 | 611.34 Million USD | -6.64% |
| 2016 Q2 | 558.13 Million USD | -8.7% |
| 2015 Q2 | 415.96 Million USD | -6.46% |
| 2015 FY | 654.83 Million USD | 38.92% |
| 2015 Q3 | 391.14 Million USD | -5.97% |
| 2015 Q1 | 444.68 Million USD | -5.66% |
| 2015 Q4 | 654.83 Million USD | 67.42% |
| 2014 Q4 | 471.37 Million USD | 151.37% |
| 2014 FY | 471.37 Million USD | 71.93% |
| 2014 Q2 | 224.06 Million USD | -8.02% |
| 2014 Q3 | 187.52 Million USD | -16.31% |
| 2014 Q1 | 243.6 Million USD | -11.15% |
| 2013 Q4 | 274.16 Million USD | -8.45% |
| 2013 FY | 274.16 Million USD | -26.26% |
| 2013 Q3 | 299.45 Million USD | -7.4% |
| 2013 Q2 | 323.39 Million USD | -6.88% |
| 2013 Q1 | 347.27 Million USD | -6.59% |
| 2012 Q3 | 357.83 Million USD | -6.09% |
| 2012 Q4 | 371.77 Million USD | 3.9% |
| 2012 Q2 | 381.06 Million USD | -5.4% |
| 2012 Q1 | 402.79 Million USD | -6.44% |
| 2012 FY | 371.77 Million USD | -13.64% |
| 2011 Q1 | 343.4 Million USD | -6.4% |
| 2011 FY | 430.51 Million USD | 17.34% |
| 2011 Q4 | 430.51 Million USD | 46.08% |
| 2011 Q3 | 294.7 Million USD | -6.71% |
| 2011 Q2 | 315.91 Million USD | -8.01% |
| 2010 Q3 | 370.87 Million USD | 1.57% |
| 2010 Q4 | 366.88 Million USD | -1.08% |
| 2010 FY | 366.88 Million USD | 42.33% |
| 2010 Q1 | 409.21 Million USD | 58.76% |
| 2010 Q2 | 365.15 Million USD | -10.77% |
| 2009 Q4 | 257.76 Million USD | 15.23% |
| 2009 Q1 | 244.45 Million USD | -6.52% |
| 2009 Q2 | 244.33 Million USD | -0.05% |
| 2009 Q3 | 223.68 Million USD | -8.45% |
| 2009 FY | 257.76 Million USD | -1.43% |
| 2008 Q1 | 336.57 Million USD | -8.86% |
| 2008 FY | 261.5 Million USD | -29.19% |
| 2008 Q4 | 261.5 Million USD | -7.82% |
| 2008 Q3 | 283.7 Million USD | -8.57% |
| 2008 Q2 | 310.3 Million USD | -7.8% |
| 2007 Q1 | 167.36 Million USD | -12.03% |
| 2007 FY | 369.29 Million USD | 94.09% |
| 2007 Q4 | 369.29 Million USD | -2.35% |
| 2007 Q3 | 378.19 Million USD | 88.19% |
| 2007 Q2 | 200.96 Million USD | 20.07% |
| 2006 FY | 190.26 Million USD | -13.01% |
| 2006 Q2 | 182.67 Million USD | -10.15% |
| 2006 Q3 | 165.34 Million USD | -9.48% |
| 2006 Q4 | 190.26 Million USD | 15.07% |
| 2006 Q1 | 203.3 Million USD | -7.05% |
| 2005 FY | 218.71 Million USD | 3.18% |
| 2005 Q2 | 192.14 Million USD | 1.72% |
| 2005 Q3 | 208.96 Million USD | 8.75% |
| 2005 Q4 | 218.71 Million USD | 4.66% |
| 2005 Q1 | 188.9 Million USD | -10.88% |
| 2004 FY | 211.98 Million USD | -25.41% |
| 2004 Q4 | 211.98 Million USD | -1.47% |
| 2004 Q3 | 215.13 Million USD | -2.73% |
| 2004 Q2 | 221.17 Million USD | -15.88% |
| 2004 Q1 | 262.93 Million USD | -7.48% |
| 2003 Q2 | 173.39 Million USD | -4.71% |
| 2003 FY | 284.19 Million USD | 40.85% |
| 2003 Q1 | 181.96 Million USD | -9.82% |
| 2003 Q3 | 209.38 Million USD | 20.76% |
| 2003 Q4 | 284.19 Million USD | 35.73% |
| 2002 FY | 201.77 Million USD | -15.92% |
| 2002 Q4 | 201.77 Million USD | 1.45% |
| 2002 Q2 | 213.83 Million USD | -5.6% |
| 2002 Q3 | 198.88 Million USD | -6.99% |
| 2002 Q1 | 226.52 Million USD | -5.61% |
| 2001 Q2 | 221.99 Million USD | 3.31% |
| 2001 FY | 239.99 Million USD | 8.74% |
| 2001 Q3 | 249.68 Million USD | 12.47% |
| 2001 Q4 | 239.99 Million USD | -3.88% |
| 2001 Q1 | 214.89 Million USD | -2.63% |
| 2000 Q1 | 20.91 Million USD | 0.0% |
| 2000 Q3 | 221.11 Million USD | -0.42% |
| 2000 FY | 220.69 Million USD | 889.65% |
| 2000 Q2 | 222.04 Million USD | 961.4% |
| 2000 Q4 | 220.69 Million USD | -0.19% |
| 1999 FY | 22.3 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 84.582% |
| Alkermes plc | 2.13 Billion USD | 89.26% |
| Agenus Inc. | 313.91 Million USD | 26.913% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 94.009% |
| Aptorum Group Limited | 20.64 Million USD | -1011.57% |
| Ardelyx, Inc. | 297.57 Million USD | 22.901% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 70.031% |
| Bicycle Therapeutics plc | 595.34 Million USD | 61.463% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -211.293% |
| ChromaDex Corporation | 54.96 Million USD | -317.417% |
| Chimerix, Inc. | 212.77 Million USD | -7.828% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -711.495% |
| Caribou Biosciences, Inc. | 440.96 Million USD | 47.972% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 89.71% |
| Precision BioSciences, Inc. | 159.78 Million USD | -43.59% |
| Dyadic International, Inc. | 8.21 Million USD | -2691.366% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -622.839% |
| Fortress Biotech, Inc. | 167.52 Million USD | -36.951% |
| Lantern Pharma Inc. | 43.64 Million USD | -425.639% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -42.205% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -1481.544% |
| Incyte Corporation | 6.78 Billion USD | 96.617% |
| IO Biotech, Inc. | 150.71 Million USD | -52.224% |
| Jaguar Health, Inc. | 50.76 Million USD | -351.961% |
| Novavax, Inc. | 1.85 Billion USD | 87.634% |
| Janux Therapeutics, Inc. | 380.4 Million USD | 39.689% |
| Opthea Limited | 188.79 Million USD | -21.525% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 72.46% |
| ContextLogic Inc. | 423 Million USD | 45.761% |
| MiMedx Group, Inc. | 239.04 Million USD | 4.023% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -32.064% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -4337.955% |
| NextCure, Inc. | 129.41 Million USD | -77.278% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -325.278% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -524.654% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -610.285% |
| Vaxcyte, Inc. | 1.4 Billion USD | 83.704% |
| PDS Biotechnology Corporation | 59.39 Million USD | -286.309% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 64.182% |
| Pharming Group N.V. | 462.85 Million USD | 50.432% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -493.146% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 63.499% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -1112.391% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -1112.391% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -38.779% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -406.611% |
| Acelyrin, Inc. | 742.69 Million USD | 69.108% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -3383.31% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -3483.149% |
| Summit Therapeutics Inc. | 202.94 Million USD | -13.048% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -208.48% |
| Senti Biosciences, Inc. | 119.48 Million USD | -92.017% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -0.476% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -36.424% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -2676.582% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -4706.036% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 51.101% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -85.543% |
| Wave Life Sciences Ltd. | 274.94 Million USD | 16.556% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 51.479% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -2170.45% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -6.957% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -20164.733% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 44.561% |
| Immix Biopharma, Inc. | 19.92 Million USD | -1051.454% |
| Keros Therapeutics, Inc. | 370.02 Million USD | 37.996% |
| MEI Pharma, Inc. | 41.37 Million USD | -454.511% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -607.983% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 32.679% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -95.717% |
| Fortress Biotech, Inc. | 167.52 Million USD | -36.951% |
| Precigen, Inc. | 151.04 Million USD | -51.896% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -574.434% |
| AlloVir, Inc. | 190.79 Million USD | -20.248% |
| C4 Therapeutics, Inc. | 376.45 Million USD | 39.055% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 54.678% |
| ImmuCell Corporation | 43.8 Million USD | -423.714% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 64.666% |
| Onconetix, Inc. | 88.82 Million USD | -158.304% |
| PureTech Health plc | 693.97 Million USD | 66.94% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -134.866% |
| Elevation Oncology, Inc. | 89.09 Million USD | -157.522% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -3599.274% |
| Seer, Inc. | 436.26 Million USD | 47.411% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -181.173% |
| Innoviva, Inc. | 1.24 Billion USD | 81.55% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -73.255% |
| ESSA Pharma Inc. | 149.12 Million USD | -53.853% |
| GlycoMimetics, Inc. | 45.31 Million USD | -406.282% |
| GT Biopharma, Inc. | 14.1 Million USD | -1526.118% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | 25.484% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | 5.078% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 51.383% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -352.549% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -140.966% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -36225.738% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 59.489% |
| Aptose Biosciences Inc. | 12.92 Million USD | -1675.417% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -937.47% |
| Soligenix, Inc. | 9.79 Million USD | -2241.751% |
| Century Therapeutics, Inc. | 360.69 Million USD | 36.392% |
| Kura Oncology, Inc. | 448.93 Million USD | 48.895% |
| TScan Therapeutics, Inc. | 272.14 Million USD | 15.697% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -1226.563% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -106.858% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -11.834% |
| Autolus Therapeutics plc | 375.38 Million USD | 38.881% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | 8.825% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | 35.406% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -366.965% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 65.298% |
| GRI Bio, Inc. | 2.95 Million USD | -7661.468% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -2063.358% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -34.551% |
| IGM Biosciences, Inc. | 423.41 Million USD | 45.814% |
| INmune Bio, Inc. | 57 Million USD | -302.5% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -3.111% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -173.321% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -778.471% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -3233.176% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -204.986% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -55.801% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -38.624% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 63.56% |
| Verastem, Inc. | 149.71 Million USD | -53.241% |
| Abeona Therapeutics Inc. | 64 Million USD | -258.472% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 55.203% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -48.539% |
| Histogen Inc. | 19.07 Million USD | -1102.899% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -912.924% |
| Surrozen, Inc. | 46.08 Million USD | -397.893% |
| Organovo Holdings, Inc. | 6.34 Million USD | -3513.624% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -5224.884% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -59.296% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -1843.984% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -204.816% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -2593.066% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | 36.791% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -1167.956% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 46.57% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -1719.173% |
| Apollomics, Inc. | 55.38 Million USD | -314.229% |
| Amarin Corporation plc | 831.68 Million USD | 72.414% |
| Mesoblast Limited | 669.15 Million USD | 65.714% |
| Turnstone Biologics Corp. | 112.81 Million USD | -103.367% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 60.152% |
| Synaptogenix, Inc. | 31.11 Million USD | -637.39% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -1783.035% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 58.138% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -3806.996% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -3023.54% |
| Exelixis, Inc. | 2.94 Billion USD | 92.203% |
| Better Therapeutics, Inc. | 22.94 Million USD | -899.996% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | 37.063% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 70.912% |
| NLS Pharmaceutics AG | 1.84 Million USD | -12324.126% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -2775.542% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -1461.273% |
| Gritstone bio, Inc. | 177.76 Million USD | -29.06% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -140.542% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -1184.434% |
| Avid Bioservices, Inc. | 336.55 Million USD | 31.831% |
| Insmed Incorporated | 1.32 Billion USD | 82.748% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -2282.85% |
| MediWound Ltd. | 66.45 Million USD | -245.219% |
| OmniAb, Inc. | 401.98 Million USD | 42.926% |
| Alector, Inc. | 621.82 Million USD | 63.104% |
| Seres Therapeutics, Inc. | 358.6 Million USD | 36.021% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -4166.065% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -304.694% |
| Zai Lab Limited | 1.03 Billion USD | 77.861% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 52.048% |
| Aura Biosciences, Inc. | 255.07 Million USD | 10.054% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 69.411% |
| Immunic, Inc. | 54.29 Million USD | -322.529% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | 13.821% |
| Veracyte, Inc. | 1.13 Billion USD | 79.836% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -1840.567% |
| FibroGen, Inc. | 423.52 Million USD | 45.829% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -6430.857% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -4743.744% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -4125.618% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 97.986% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -2505.667% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 55.662% |
| TG Therapeutics, Inc. | 329.58 Million USD | 30.389% |
| Galecto, Inc. | 38.22 Million USD | -500.175% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -700.073% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 94.734% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | 2.538% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -823.553% |
| XBiotech Inc. | 227.24 Million USD | -0.962% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -140.542% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -60.89% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | 19.757% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -79.425% |
| Theravance Biopharma, Inc. | 381.99 Million USD | 39.94% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 84.613% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | 37.116% |
| Vaxxinity, Inc. | 44.35 Million USD | -417.28% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 55.62% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -1132.871% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | 24.79% |
| NexImmune, Inc. | 8.59 Million USD | -2569.657% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -2041.157% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -1239.544% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.306% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -935.744% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -58388.267% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -32.366% |
| Ainos, Inc. | 31.84 Million USD | -620.528% |
| Pluri Inc. | 39.52 Million USD | -480.436% |
| Prothena Corporation plc | 696.38 Million USD | 67.054% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | 18.82% |
| Celularity Inc. | 143.88 Million USD | -59.449% |
| Rallybio Corporation | 115.62 Million USD | -98.434% |
| Cue Biopharma, Inc. | 61.53 Million USD | -272.873% |
| MeiraGTx Holdings plc | 458.16 Million USD | 49.925% |
| Omeros Corporation | 378.26 Million USD | 39.348% |
| Humacyte, Inc. | 128.22 Million USD | -78.93% |
| Immunocore Holdings plc | 597 Million USD | 61.57% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -633.961% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -234.786% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 78.134% |
| CalciMedica, Inc. | 12.18 Million USD | -1782.881% |
| Cabaletta Bio, Inc. | 253.65 Million USD | 9.549% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -34.241% |
| Scholar Rock Holding Corporation | 311.03 Million USD | 26.237% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 59.415% |
| Pulmatrix, Inc. | 33.95 Million USD | -575.626% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -745.167% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -62.88% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 82.365% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -76.228% |
| Cytokinetics, Incorporated | 824.31 Million USD | 72.167% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -986.157% |
| Nutriband Inc. | 7.51 Million USD | -2952.073% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -190.586% |
| Vor Biopharma Inc. | 209.82 Million USD | -9.341% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 96.823% |
| Evogene Ltd. | 51.1 Million USD | -348.972% |
| ProKidney Corp. | 420.55 Million USD | 45.446% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -318.414% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -2309.898% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 58.009% |
| CorMedix Inc. | 82.05 Million USD | -179.587% |
| BioLineRx Ltd. | 63.92 Million USD | -258.903% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 43.008% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -713.578% |
| Atai Life Sciences N.V. | 293.47 Million USD | 21.824% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -40.642% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -80.06% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 59.178% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -137.212% |
| MediciNova, Inc. | 66.26 Million USD | -246.204% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -160.869% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -5041.422% |
| GeoVax Labs, Inc. | 9.28 Million USD | -2371.438% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 60.997% |
| Biomea Fusion, Inc. | 199.92 Million USD | -14.756% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 87.945% |
| Mereo BioPharma Group plc | 66.49 Million USD | -245.011% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 52.704% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 62.565% |
| Absci Corporation | 234.48 Million USD | 2.154% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -3036.418% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | 32.499% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -38.979% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 56.409% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | 17.38% |
| Allakos Inc. | 243.61 Million USD | 5.821% |
| Imunon, Inc. | 21.91 Million USD | -946.757% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | 10.968% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 63.086% |
| BioAtla, Inc. | 119.65 Million USD | -91.737% |
| NLS Pharmaceutics AG | 1.84 Million USD | -12324.126% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -7025.124% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 64.31% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -139.15% |
| XOMA Corporation | 234.3 Million USD | 2.079% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -3.704% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -82.312% |
| aTyr Pharma, Inc. | 122.06 Million USD | -87.953% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -49.074% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 60.462% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 53.218% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -107.686% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -1413.628% |
| Akari Therapeutics, Plc | 4.35 Million USD | -5168.175% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -1246.625% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 86.763% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -7339.366% |
| UroGen Pharma Ltd. | 178.31 Million USD | -28.668% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 51.262% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -41185.371% |
| Orgenesis Inc. | 14.55 Million USD | -1476.615% |
| Entera Bio Ltd. | 11.76 Million USD | -1850.098% |
| GH Research PLC | 226.3 Million USD | -1.383% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -319.477% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -113.549% |
| Xencor, Inc. | 952.69 Million USD | 75.918% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -2847.53% |
| Replimune Group, Inc. | 487.72 Million USD | 52.959% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -2742.603% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 64.618% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -7339.366% |
| Portage Biotech Inc. | 7.77 Million USD | -2849.338% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -5041.422% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | 17.157% |
| OncoCyte Corporation | 74.89 Million USD | -206.346% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -11183.867% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -3864.803% |
| Purple Biotech Ltd. | 44.3 Million USD | -417.875% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -572.3% |
| scPharmaceuticals Inc. | 94.47 Million USD | -142.836% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -1171.43% |
| HilleVax, Inc. | 344.43 Million USD | 33.39% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -7123.835% |
| Tharimmune, Inc. | 10.94 Million USD | -1995.932% |
| Genprex, Inc. | 10.67 Million USD | -2050.106% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 53.762% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -138.363% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -9357.09% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -5407.916% |
| OKYO Pharma Limited | 1.54 Million USD | -14785.769% |
| Savara Inc. | 177.56 Million USD | -29.209% |
| Curis, Inc. | 77.28 Million USD | -196.872% |
| Daré Bioscience, Inc. | 21.28 Million USD | -978.032% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -258.77% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -2737.361% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -1084.394% |
| BeiGene, Ltd. | 5.8 Billion USD | 96.048% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -1785.356% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 89.015% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | 35.905% |
| Erasca, Inc. | 395.29 Million USD | 41.96% |
| bluebird bio, Inc. | 619.16 Million USD | 62.945% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -5206.718% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 96.647% |
| DBV Technologies S.A. | 182.98 Million USD | -25.381% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -5206.718% |
| Moderna, Inc. | 18.42 Billion USD | 98.755% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -1159.423% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -1880.226% |
| Molecular Templates, Inc. | 35.38 Million USD | -548.416% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -65.934% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 70.918% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | 24.469% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -120.719% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 50.727% |
| Cogent Biosciences, Inc. | 313.43 Million USD | 26.802% |
| MacroGenics, Inc. | 306.82 Million USD | 25.224% |
| RenovoRx, Inc. | 1.46 Million USD | -15550.0% |
| Adicet Bio, Inc. | 207.29 Million USD | -10.678% |
| Prime Medicine, Inc. | 193.85 Million USD | -18.353% |
| Aditxt, Inc. | 44.57 Million USD | -414.665% |
| Adagene Inc. | 115.72 Million USD | -98.247% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -5050.859% |
| Quantum-Si incorporated | 298.25 Million USD | 23.075% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 84.576% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -2876.071% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | 34.688% |
| SciSparc Ltd. | 11.18 Million USD | -1951.771% |
| Vericel Corporation | 353.65 Million USD | 35.127% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -1778.624% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -303.21% |
| Generation Bio Co. | 374.75 Million USD | 38.779% |
| Astria Therapeutics, Inc. | 254.66 Million USD | 9.91% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -44.689% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | 32.791% |
| Invivyd, Inc. | 229.18 Million USD | -0.108% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 72.816% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -1785.31% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -25.79% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -1023.33% |
| 2seventy bio, Inc. | 565.42 Million USD | 59.424% |
| ADMA Biologics, Inc. | 329.18 Million USD | 30.303% |
| Clene Inc. | 52.34 Million USD | -338.335% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -290.622% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -76.628% |
| GeoVax Labs, Inc. | 9.28 Million USD | -2371.438% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 64.903% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -121.433% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -75.961% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -135.186% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -223.153% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | 5.411% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 88.295% |
| Evaxion Biotech A/S | 12.88 Million USD | -1680.09% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | 8.978% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 69.519% |
| Trevena, Inc. | 40.6 Million USD | -465.026% |
| Surrozen, Inc. | 46.08 Million USD | -397.893% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -1.582% |
| Cingulate Inc. | 3.49 Million USD | -6471.193% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -1279.692% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -249.26% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -1863.512% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | 14.557% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 69.367% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -82.243% |
| Clearmind Medicine Inc. | 4.32 Million USD | -5205.466% |
| Kronos Bio, Inc. | 213.27 Million USD | -7.572% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -43.587% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -2580.054% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 37.738% |
| Statera Biopharma, Inc. | 21.16 Million USD | -983.762% |
| ImmunityBio, Inc. | 504.45 Million USD | 54.519% |
| Korro Bio, Inc. | 221.66 Million USD | -3.504% |
| Kineta, Inc. | 10.28 Million USD | -2131.583% |
| BioVie Inc. | 25.2 Million USD | -810.131% |
| Codexis, Inc. | 136.56 Million USD | -68.005% |
| Celularity Inc. | 143.88 Million USD | -59.449% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 63.89% |
| Celcuity Inc. | 191.21 Million USD | -19.982% |
| Virax Biolabs Group Limited | 5.48 Million USD | -4083.631% |
| Cibus, Inc. | 544.41 Million USD | 57.857% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -82.24% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -1016.769% |
| IN8bio, Inc. | 33.7 Million USD | -580.616% |
| Kodiak Sciences Inc. | 479.37 Million USD | 52.14% |
| Annexon, Inc. | 297.67 Million USD | 22.926% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -32.61% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -66.895% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -992.883% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 92.327% |
| Eyenovia, Inc. | 28.77 Million USD | -697.199% |
| Puma Biotechnology, Inc. | 230.52 Million USD | 0.477% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -3075.927% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -276.57% |
| Arcellx, Inc. | 825.13 Million USD | 72.195% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -181.036% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 50.37% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -646.111% |
| Moolec Science SA | 24.05 Million USD | -853.916% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | 26.02% |
| Geron Corporation | 394.07 Million USD | 41.781% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -125.572% |
| Royalty Pharma plc | 16.38 Billion USD | 98.599% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 61.438% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -3179.987% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -1807.566% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -1.49% |
| Humacyte, Inc. | 128.22 Million USD | -78.93% |
| Structure Therapeutics Inc. | 482.01 Million USD | 52.402% |
| 89bio, Inc. | 596.26 Million USD | 61.523% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | 9.012% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -12301.568% |
| Genelux Corporation | 27.89 Million USD | -722.533% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -156.623% |
| Notable Labs, Ltd. | 19.54 Million USD | -1074.09% |
| Liquidia Corporation | 120.43 Million USD | -90.507% |
| Mustang Bio, Inc. | 17.74 Million USD | -1193.141% |
| Immunovant, Inc. | 666.71 Million USD | 65.588% |
| Quantum-Si incorporated | 298.25 Million USD | 23.075% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -58.883% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -323.613% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -30.695% |
| Acasti Pharma Inc. | 73.3 Million USD | -213.0% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -4939.869% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -778.471% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 76.22% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -4320.667% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -907.107% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -344.604% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -26.973% |
| PepGen Inc. | 143.05 Million USD | -60.382% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -500.332% |
| United Therapeutics Corporation | 7.16 Billion USD | 96.799% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -1095.877% |
| Solid Biosciences Inc. | 164.93 Million USD | -39.099% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -3806.996% |
| Immuneering Corporation | 102.58 Million USD | -123.649% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -5224.884% |
| Silo Pharma, Inc. | 7.74 Million USD | -2861.849% |
| Belite Bio, Inc | 94.64 Million USD | -142.418% |
| XOMA Corporation | 234.3 Million USD | 2.079% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | 1.612% |
| Bionomics Limited | 27.64 Million USD | -729.789% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 42.843% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -113.645% |
| uniQure N.V. | 831.68 Million USD | 72.414% |
| Cassava Sciences, Inc. | 151.66 Million USD | -51.276% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -5050.859% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | 16.232% |
| Forte Biosciences, Inc. | 38.98 Million USD | -488.581% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -5532.766% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -522.924% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -3075.927% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -6430.857% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -1840.859% |
| Altimmune, Inc. | 210.64 Million USD | -8.92% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 70.506% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -113.645% |
| Compugen Ltd. | 121.33 Million USD | -89.089% |
| Peak Bio, Inc. | 2.59 Million USD | -8736.376% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -33.136% |
| Benitec Biopharma Inc. | 52.21 Million USD | -339.435% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | 32.888% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -559.791% |
| Zura Bio Limited | 100.84 Million USD | -127.511% |
| PolyPid Ltd. | 15.37 Million USD | -1392.512% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -92.335% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -559.791% |
| Instil Bio, Inc. | 325.63 Million USD | 29.543% |
| argenx SE | 4.54 Billion USD | 94.949% |
| Immunome, Inc. | 148.54 Million USD | -54.456% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -46.25% |
| Verona Pharma plc | 308.12 Million USD | 25.54% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -163.836% |
| Shattuck Labs, Inc. | 159.56 Million USD | -43.785% |
| CervoMed Inc. | 9.97 Million USD | -2200.612% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -21.741% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -1914.656% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -27.883% |
| Moolec Science SA | 24.05 Million USD | -853.916% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -3650.384% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -32.661% |
| AnaptysBio, Inc. | 452.38 Million USD | 49.285% |
| Design Therapeutics, Inc. | 289.64 Million USD | 20.789% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -215.042% |
| NeurAxis, Inc. | 509.49 Thousand USD | -44930.402% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -4134.57% |
| Lumos Pharma, Inc. | 40.63 Million USD | -464.568% |
| Achilles Therapeutics plc | 161.45 Million USD | -42.1% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -163.836% |
| 180 Life Sciences Corp. | 5.25 Million USD | -4262.203% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -225.765% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -2580.054% |
| Nutriband Inc. | 7.51 Million USD | -2952.073% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | 9.917% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -15.117% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -201.041% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -296.141% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 56.427% |
| Palisade Bio, Inc. | 14.05 Million USD | -1532.714% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -9.099% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 84.283% |
| Neurogene Inc. | 222.57 Million USD | -3.08% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 64.519% |
| AEON Biopharma, Inc. | 6.84 Million USD | -3251.775% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 49.357% |
| Sesen Bio, Inc. | 189.17 Million USD | -21.279% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | 15.61% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -1573.215% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 70.599% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | 14.07% |
| Athira Pharma, Inc. | 160.24 Million USD | -43.174% |
| Vaccinex, Inc. | 3.63 Million USD | -6218.617% |
| HCW Biologics Inc. | 28.51 Million USD | -704.628% |
| XOMA Corporation | 234.3 Million USD | 2.079% |
| Nektar Therapeutics | 398.03 Million USD | 42.359% |
| Arvinas, Inc. | 1.3 Billion USD | 82.414% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -1246.625% |
| Merus N.V. | 458.49 Million USD | 49.96% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -12.264% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -27.316% |
| Rezolute, Inc. | 132.73 Million USD | -72.845% |
| Clene Inc. | 52.34 Million USD | -338.335% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -1437.328% |
| BeyondSpring Inc. | 24.8 Million USD | -824.819% |
| Synlogic, Inc. | 75.55 Million USD | -203.678% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -1834.151% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -2350.117% |
| Peak Bio, Inc. | 2.59 Million USD | -8736.376% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -31.228% |
| Krystal Biotech, Inc. | 818.35 Million USD | 71.965% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | 4.579% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 68.389% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -6313.694% |
| MannKind Corporation | 475.19 Million USD | 51.719% |
| Ikena Oncology, Inc. | 192.09 Million USD | -19.437% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -1615.485% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -96.869% |
| Gossamer Bio, Inc. | 311.91 Million USD | 26.445% |
| CohBar, Inc. | 16.36 Million USD | -1301.892% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -552.473% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -3036.418% |
| Legend Biotech Corporation | 1.84 Billion USD | 87.589% |
| Mural Oncology plc | 301.74 Million USD | 23.966% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -634.996% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -3938.955% |
| Disc Medicine, Inc. | 367.99 Million USD | 37.654% |
| Champions Oncology, Inc. | 26.13 Million USD | -777.962% |
| REGENXBIO Inc. | 573.97 Million USD | 60.028% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -8372.001% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -48.607% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -1799.942% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | 32.528% |
| Vaxart, Inc. | 91.83 Million USD | -149.841% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -282.995% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -54.678% |
| Cellectis S.A. | 334.27 Million USD | 31.364% |
| Longeveron Inc. | 12.17 Million USD | -1783.963% |
| Repare Therapeutics Inc. | 253.9 Million USD | 9.638% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 92.972% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -14.231% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 89.015% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -14018.708% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | 17.386% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -40.669% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -65.361% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -798.946% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 98.991% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 80.117% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -1778.624% |
| Veru Inc. | 50.59 Million USD | -353.454% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -403.653% |
| Cingulate Inc. | 3.49 Million USD | -6471.193% |
| Passage Bio, Inc. | 150.54 Million USD | -52.399% |
| Context Therapeutics Inc. | 16.06 Million USD | -1328.331% |
| Exicure, Inc. | 11.58 Million USD | -1881.252% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | 38.989% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -41.937% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -1213.124% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | 31.05% |
| Nuvalent, Inc. | 732.38 Million USD | 68.674% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -1435.25% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -156.191% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -1516.722% |
| OmniAb, Inc. | 401.98 Million USD | 42.926% |
| Anew Medical, Inc. | 19.45 Million USD | -1079.223% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -758.431% |
| Lipocine Inc. | 23 Million USD | -897.471% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -64.104% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | 24.916% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -173.321% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -88.768% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -2791.355% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 73.996% |
| Ocugen, Inc. | 64.54 Million USD | -255.445% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -84.22% |
| Q32 Bio Inc. | 306.11 Million USD | 25.052% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -5352.21% |
| Alumis Inc. Common Stock | 89.61 Million USD | -156.025% |
| Equillium, Inc. | 50.53 Million USD | -354.045% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -205.112% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -455.875% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -13389.055% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -777.66% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -256.03% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -6055.676% |
| Dominari Holdings Inc. | 57.55 Million USD | -298.605% |
| Edesa Biotech, Inc. | 8.89 Million USD | -2480.627% |
| vTv Therapeutics Inc. | 11.01 Million USD | -1982.311% |
| Bio-Techne Corporation | 2.81 Billion USD | 91.845% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 75.518% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 71.726% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | 17.372% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -450.163% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 65.633% |
| Nkarta, Inc. | 378.88 Million USD | 39.446% |
| BioCardia, Inc. | 2.98 Million USD | -7580.917% |
| Iterum Therapeutics plc | 26.25 Million USD | -773.716% |